インスリングラルギン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "インスリングラルギン" in Japanese language version.

refsWebsite

Global rank Japanese rank

12nih.gov

4^th place

24^th place

8doi.org

2^nd place

6^th place

4europa.eu

68^th place

425^th place

3drugs.com

399^th place

1,603^rd place

3pmda.go.jp

6,690^th place

394^th place

2web.archive.org

1^st place

1medicines.org.uk

3,823^rd place

low place

1handle.net

102^nd place

78^th place

1warwick.ac.uk

4,378^th place

low place

1springer.com

274^th place

596^th place

1harvard.edu

18^th place

107^th place

1sanofi.us

low place

1fda.gov

447^th place

1,043^rd place

1dm-net.co.jp

low place

dm-net.co.jp (Global: low place; Japanese: low place)

“次世代の基礎インスリン「ランタスXR注ソロスター」承認取得低血糖発現と体重増加が低下｜ニュース｜糖尿病ネットワーク”. ニュース｜糖尿病ネットワーク. 2022年1月19日閲覧。

doi.org (Global: 2^nd place; Japanese: 6^th place)

Waugh, N; Cummins, E; Royle, P; Clar, C; Marien, M; Richter, B; Philip, S (July 2010). “Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation”. Health Technology Assessment 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.
“Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis”. CMAJ 180 (4): 385–97. (February 2009). doi:10.1503/cmaj.081041. PMC 2638025. PMID 19221352.
“Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial”. Advances in Therapy 37 (5): 2413-2426. (April 2020). doi:10.1007/s12325-020-01332-y. PMC 7467476. PMID 32306247.
American Diabetes Association (2003). “Position statement: Insulin administration”. Diabetes Care 26 (Suppl. 1): 121–124. doi:10.2337/diacare.26.2007.S121. PMID 12502637.
Kaplan, W. (2004). “Effects of Mixing Glargine and Short-Acting Insulin Analogs on Glucose Control”. Diabetes Care 27 (11): 2739–2740. doi:10.2337/diacare.27.11.2739. PMID 15505016.
Rendell, M; Akturk, HK; Tella, SH (March 2013). “Glargine safety, diabetes and cancer.”. Expert Opinion on Drug Safety 12 (2): 247–63. doi:10.1517/14740338.2013.770469. PMID 23394441.
Tang, X; Yang, L; He, Z; Liu, J (2012). “Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.”. PLOS ONE 7 (12): e51814. Bibcode: 2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.
Bolli, G. (1999). “Insulin analogues and their potential in the management of diabetes mellitus.”. Diabetologia 42 (10): 1151–1167. doi:10.1007/s001250051286. PMID 10525654.

drugs.com (Global: 399^th place; Japanese: 1,603^rd place)

“Insulin glargine Use During Pregnancy”. Drugs.com (2020年4月6日). 2020年9月4日閲覧。
“Insulin Glargine Monograph for Professionals”. Drugs.com. AHFS. 2018年12月23日閲覧。
“Insulin Glargine Monograph for Professionals”. Drugs.com. AHFS. 2018年12月23日閲覧。

europa.eu (Global: 68^th place; Japanese: 425^th place)

ema.europa.eu

“Lantus EPAR”. European Medicines Agency (EMA). 2021年7月28日閲覧。
“Toujeo EPAR”. European Medicines Agency (EMA). 2021年7月28日閲覧。
“Lantus EPAR”. European Medicines Agency (EMA). 2020年5月7日閲覧。

emea.europa.eu

EPAR Lantus Archived 22 November 2006 at the Wayback Machine., German summary of admission report of EMEA (PDF)

fda.gov (Global: 447^th place; Japanese: 1,043^rd place)

accessdata.fda.gov

“Toujeo: FDA-Approved Drugs”. U.S. Food and Drug Administration (FDA). 2020年5月7日閲覧。

handle.net (Global: 102^nd place; Japanese: 78^th place)

hdl.handle.net

World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. (2021). hdl:10665/345533. WHO/MHP/HPS/EML/2021.02

harvard.edu (Global: 18^th place; Japanese: 107^th place)

ui.adsabs.harvard.edu

Tang, X; Yang, L; He, Z; Liu, J (2012). “Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.”. PLOS ONE 7 (12): e51814. Bibcode: 2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.

medicines.org.uk (Global: 3,823^rd place; Japanese: low place)

“Lantus 100 units/ml solution for injection in a cartridge - Summary of Product Characteristics (SmPC)”. (emc). 2020年5月7日閲覧。

nih.gov (Global: 4^th place; Japanese: 24^th place)

pubmed.ncbi.nlm.nih.gov

Waugh, N; Cummins, E; Royle, P; Clar, C; Marien, M; Richter, B; Philip, S (July 2010). “Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation”. Health Technology Assessment 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.
“Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis”. CMAJ 180 (4): 385–97. (February 2009). doi:10.1503/cmaj.081041. PMC 2638025. PMID 19221352.
“Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial”. Advances in Therapy 37 (5): 2413-2426. (April 2020). doi:10.1007/s12325-020-01332-y. PMC 7467476. PMID 32306247.
American Diabetes Association (2003). “Position statement: Insulin administration”. Diabetes Care 26 (Suppl. 1): 121–124. doi:10.2337/diacare.26.2007.S121. PMID 12502637.
Kaplan, W. (2004). “Effects of Mixing Glargine and Short-Acting Insulin Analogs on Glucose Control”. Diabetes Care 27 (11): 2739–2740. doi:10.2337/diacare.27.11.2739. PMID 15505016.
Rendell, M; Akturk, HK; Tella, SH (March 2013). “Glargine safety, diabetes and cancer.”. Expert Opinion on Drug Safety 12 (2): 247–63. doi:10.1517/14740338.2013.770469. PMID 23394441.
Tang, X; Yang, L; He, Z; Liu, J (2012). “Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.”. PLOS ONE 7 (12): e51814. Bibcode: 2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.
Bolli, G. (1999). “Insulin analogues and their potential in the management of diabetes mellitus.”. Diabetologia 42 (10): 1151–1167. doi:10.1007/s001250051286. PMID 10525654.

pmc.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

“Lantus- insulin glargine injection, solution Lantus SoloStar- insulin glargine injection, solution”. DailyMed. 2021年7月29日閲覧。

pmda.go.jp (Global: 6,690^th place; Japanese: 394^th place)

info.pmda.go.jp

“ランタス注100単位／mL 添付文書”. www.info.pmda.go.jp. 2022年1月19日閲覧。
“ランタスXR注ソロスター添付文書”. www.info.pmda.go.jp. 2022年1月19日閲覧。

pmda.go.jp

“ランタスXR注ソロスター CTD 第二部”. PMDA. 2022年1月19日閲覧。

sanofi.us (Global: low place; Japanese: low place)

news.sanofi.us

“Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo” (Press release). Sanofi. 25 February 2015. 2015年2月27日時点のオリジナルよりアーカイブ.

springer.com (Global: 274^th place; Japanese: 596^th place)

link.springer.com

“Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial”. Advances in Therapy 37 (5): 2413-2426. (April 2020). doi:10.1007/s12325-020-01332-y. PMC 7467476. PMID 32306247.

warwick.ac.uk (Global: 4,378^th place; Japanese: low place)

wrap.warwick.ac.uk

Waugh, N; Cummins, E; Royle, P; Clar, C; Marien, M; Richter, B; Philip, S (July 2010). “Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation”. Health Technology Assessment 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.

web.archive.org (Global: 1^st place; Japanese: 1^st place)

EPAR Lantus Archived 22 November 2006 at the Wayback Machine., German summary of admission report of EMEA (PDF)
“Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo” (Press release). Sanofi. 25 February 2015. 2015年2月27日時点のオリジナルよりアーカイブ.

インスリン グラルギン (Japanese Wikipedia)

dm-net.co.jp (Global: low place; Japanese: low place)

doi.org (Global: 2nd place; Japanese: 6th place)

drugs.com (Global: 399th place; Japanese: 1,603rd place)

europa.eu (Global: 68th place; Japanese: 425th place)

ema.europa.eu

emea.europa.eu

fda.gov (Global: 447th place; Japanese: 1,043rd place)

accessdata.fda.gov

handle.net (Global: 102nd place; Japanese: 78th place)

hdl.handle.net

harvard.edu (Global: 18th place; Japanese: 107th place)

ui.adsabs.harvard.edu

medicines.org.uk (Global: 3,823rd place; Japanese: low place)

nih.gov (Global: 4th place; Japanese: 24th place)

pubmed.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pmda.go.jp (Global: 6,690th place; Japanese: 394th place)

info.pmda.go.jp

pmda.go.jp

sanofi.us (Global: low place; Japanese: low place)

news.sanofi.us

springer.com (Global: 274th place; Japanese: 596th place)

link.springer.com

warwick.ac.uk (Global: 4,378th place; Japanese: low place)

wrap.warwick.ac.uk

web.archive.org (Global: 1st place; Japanese: 1st place)

インスリングラルギン (Japanese Wikipedia)

doi.org (Global: 2^nd place; Japanese: 6^th place)

drugs.com (Global: 399^th place; Japanese: 1,603^rd place)

europa.eu (Global: 68^th place; Japanese: 425^th place)

fda.gov (Global: 447^th place; Japanese: 1,043^rd place)

handle.net (Global: 102^nd place; Japanese: 78^th place)

harvard.edu (Global: 18^th place; Japanese: 107^th place)

medicines.org.uk (Global: 3,823^rd place; Japanese: low place)

nih.gov (Global: 4^th place; Japanese: 24^th place)

pmda.go.jp (Global: 6,690^th place; Japanese: 394^th place)

springer.com (Global: 274^th place; Japanese: 596^th place)

warwick.ac.uk (Global: 4,378^th place; Japanese: low place)

web.archive.org (Global: 1^st place; Japanese: 1^st place)